KEY FINDINGS
The United States DNA sequencing market is set to register a CAGR of 16.89% during the forecast period, 2021-2026. Technological developments, advanced healthcare infrastructure, and increasing investment in R&D propel market growth in the country.
MARKET INSIGHTS
In the United States, several programs and initiatives facilitate market growth. For instance, the precision medicine initiative cohort program encourages around 1 million participants to enhance their ability to treat and prevent diseases associated with differences in genetics, environment, and lifestyle. Also, universal newborn screening plans are conducted in the country. As per research studies, within 24-48 hours after birth, few blood drops drawn from newborns are sent to labs to screen for life-threatening disorders. Such genome sequence-based diagnostics and government plans are raising market demands in the US.
DNA sequencing has also caused a paradigm shift in proteomic and genomic research. This is attributed to its accuracy and high-throughput technology utilized for varied applications. It is adopted in many academic research institutes. For instance, in June 2020, NovaSeq 6000 Sequencing System was installed by Illumina at the Whitehead Institute for Biomedical Research, Massachusetts. Such factors boost the market growth.
COMPETITIVE INSIGHTS
Some of the market’s leading players include PerkinElmer Inc, Illumina Inc, Danaher Corporation (Integrated DNA Technologies Inc), Agilent Technologies Inc, Adaptive Biotechnologies Inc, Bio-Rad Laboratories Inc, etc.
Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation cater to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments
'
TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. SCOPE OF STUDY
1.3. METHODOLOGY
1.4. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. COUNTRY SNAPSHOT
2.3. COUNTRY ANALYSIS
2.4. KEY GROWTH ENABLERS
2.5. KEY CHALLENGES
3. KEY ANALYTICS
3.1. IMPACT OF COVID-19 ON DNA SEQUENCING MARKET
3.2. KEY MARKET TRENDS
3.3. PORTER’S FIVE FORCES ANALYSIS
3.3.1. BUYERS POWER
3.3.2. SUPPLIERS POWER
3.3.3. SUBSTITUTION
3.3.4. NEW ENTRY
3.3.5. INDUSTRY RIVALRY
3.4. OPPORTUNITY MATRIX
3.5. VENDOR LANDSCAPE
3.6. VALUE CHAIN ANALYSIS
3.7. KEY BUYING CRITERIA
4. MARKET BY TECHNOLOGY
4.1. SEQUENCING BY SYNTHESIS
4.2. ION SEMICONDUCTOR SEQUENCING
4.3. CHAIN TERMINATION SEQUENCING
4.4. PYROSEQUENCING
4.5. SEQUENCING BY LIGATION (SBL)
4.6. SINGLE-MOLECULE REAL-TIME SEQUENCING (SMRT)
4.7. NANOPORE SEQUENCING
4.8. OTHER TECHNOLOGIES
5. MARKET BY APPLICATION
5.1. BIOMARKER DISCOVERY
5.2. DIAGNOSTICS
5.3. REPRODUCTIVE HEALTH
5.4. PERSONALIZED MEDICINE
5.5. DRUG DISCOVERY
5.6. AGRICULTURE & ANIMAL RESEARCH
5.7. FORENSICS
5.8. OTHER APPLICATIONS
6. MARKET BY PRODUCT
6.1. INSTRUMENTS & CONSUMABLES
6.1.1. INSTRUMENTS & CONSUMABLES TYPE
6.1.1.1. CONSUMABLES
6.1.1.2. INSTRUMENTS
6.1.2. INSTRUMENTS & CONSUMABLES PLATFORM
6.1.2.1. NGS (NEXT GENERATION SEQUENCING)
6.1.2.1.1. RNA SEQUENCING
6.1.2.1.2. TARGETED RESEQUENCING
6.1.2.1.3. WHOLE-EXOME SEQUENCING
6.1.2.1.4. WHOLE-GENOME SEQUENCING
6.1.2.1.5. CHIP SEQUENCING
6.1.2.1.6. DE NOVO SEQUENCING
6.1.2.1.7. METHYL SEQUENCING
6.1.2.2. SANGER
6.2. SEQUENCING SERVICES
6.3. BIOINFORMATICS
7. MARKET BY END-USER
7.1. RESEARCH CENTERS AND ACADEMIC & GOVERNMENT INSTITUTES
7.2. PHARMACEUTICAL
7.3. BIOTECHNOLOGY COMPANIES
7.4. HOSPITALS & CLINICS
7.5. OTHER END-USERS
8. COMPETITIVE LANDSCAPE
8.1. KEY STRATEGIC DEVELOPMENTS
8.1.1. MERGERS & ACQUISITIONS
8.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
8.1.3. PARTNERSHIPS, CONTRACTS/AGREEMENTS & COLLABORATIONS
8.1.4. BUSINESS EXPANSIONS/ APPROVALS/ ANNOUNCEMENTS
8.2. COMPANY PROFILES
8.2.1. ADAPTIVE BIOTECHNOLOGIES INC
8.2.2. AGILENT TECHNOLOGIES INC
8.2.3. BIO-RAD LABORATORIES INC
8.2.4. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
8.2.5. ILLUMINA INC
8.2.6. PERKINELMER INC
1. ADAPTIVE BIOTECHNOLOGIES INC
2. AGILENT TECHNOLOGIES INC
3. BIO-RAD LABORATORIES INC
4. DANAHER CORPORATION (INTEGRATED DNA TECHNOLOGIES INC)
5. ILLUMINA INC
6. PERKINELMER INC
